Pain After Carpal Tunnel Release
Conditions
Brief summary
Carpal tunnel syndrome is one of the most common surgeries performed per year in the United States, accounting for over 600,000 surgeries. The procedure is commonly performed under light sedation and local anesthesia. Bupivicaine, a long acting local anesthetic, has been used to allow extended pain relief for 8-10 hours after carpal tunnel release. Exparel, a liposomal bupivicaine formulation, has been documented to provide pain relief for up to 72 hours post-operatively. By decreasing post-operative pain through the use of a long-acting local anesthetic, the use of narcotic pain medications may be decreased and patient satisfaction scores may increase. The purpose of this study is to prospectively compare bupivicaine and liposomal bupivicaine with respect to post-operative pain control, narcotic usage, and patient satisfaction after carpal tunnel release.
Interventions
DRUGBupivacaine
DRUGExparel
Sponsors
University of Pittsburgh
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* Patients with carpal tunnel syndrome undergoing surgery
Exclusion criteria
* Non english speaking * Allergy to bupivacaine or exparel
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain | Starting immediately after surgery and then every 8 hours for 10 days | Pain will be evaluated using an 11-point ordinal scale (0-10) |
Countries
United States
Outcome results
None listed